(9618675), X. J., & (1776799), Z. L. (2025). Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: Based on the SONIA trial.docx.
Chicago-viite (17. p.)(9618675), Xiaohu Jin, ja Zhifeng Li (1776799). Supplementary File 1_Cost-effectiveness Analysis of First-line Versus Second-line Use of CDK4/6 Inhibitors Combined with Endocrine Therapy in Advanced HR+/HER2- Breast Cancer in China: Based on the SONIA Trial.docx. 2025.
MLA-viite (9. p.)(9618675), Xiaohu Jin, ja Zhifeng Li (1776799). Supplementary File 1_Cost-effectiveness Analysis of First-line Versus Second-line Use of CDK4/6 Inhibitors Combined with Endocrine Therapy in Advanced HR+/HER2- Breast Cancer in China: Based on the SONIA Trial.docx. 2025.